TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26547425
Drug: GXR all-active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GXR all-active (1-4 mg/day)
Study: 26547425
Drug: GXR am
Approvals — FDA: no, EMA: no, PMDA: no
Description: GXR am (1-4 mg/day in the morning)
Study: 26547425
Drug: GXR pm
Approvals — FDA: no, EMA: no, PMDA: no
Description: GXR pm (1-4 mg/day in the evening)
Study: 23627550
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including multiple point‐of‐care interventions (e.g., standing orders, EHR reminders), performance measurement, and financial incentives.
Study: 21565135
Drug: Suoquan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suoquan Pill (SQP) 10 g per oral dose twice daily for 8 weeks
Study: 21565135
Drug: Wuling Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Powder (WLP) 10 g per oral dose twice daily for 8 weeks
Study: 21565135
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder 10 g per oral dose twice daily for 8 weeks
Study: 21565135
Drug: Suoquan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suoquan Pill (SQP) and Wuling Powder (WLP)
Study: 19276670
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy consisting of 2‐3 cycles of cisplatin and 5‐Fluorouracil followed by low dose weekly cisplatin based chemoradiotherapy (treatment arm: n = 48)
Study: 17888186
Drug: 400 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL/day of red wine for two weeks
Study: 11322056
Drug: 0.5% Apraclonidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Apraclonidin eye drops applied twice daily for 8 days
Study: 11322056
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication (0.9% NaCI) applied according to the same protocol
Study: 9063761
Drug: 19.3% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19.3% glucose polymer solution (C trial)
Study: 9063761
Drug: 6.9% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% glucose polymer solution (D trial)
Study: 26277295
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of intracoronary diltiazem
Study: 16840514
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) intravenous infusion at 125 mg kg(‐1) h(‐1) for 15 min, then 25 mg kg(‐1) h(‐1) for 20 min prior to and throughout exercise
Study: 10959784
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with quadrant root planing)
Study: 8638837
Drug: Ropivacaine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 20 mg/h
Study: 8638837
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg/h
Study: 1350610
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg four times a day)
Study: 1350610
Drug: Dimethyl sulfoxide
Normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dimethyl sulfoxide (500 mg four times a day)
Study: 1350610
Drug: Sulfasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (2 gm daily) alone
Study: 31402562
Drug: Bevacizumab (Bev)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Bev) in combination with sequential chemotherapy
Study: 28971905
Drug: 6‐methylprednisolone 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐methylprednisolone 1 mg/kg/day
Study: 12796664
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor exercises (PFE) with biofeedback and physical therapist guidance, performed before and after surgery, with home exercises twice daily after surgery.
Study: 1450186
Drug: Remoxipride (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (30 to 90 mg)
Study: 1450186
Drug: Remoxipride (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (120 to 240 mg)
Study: 1450186
Drug: Remoxipride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (300 to 600 mg)
Study: 1450186
Drug: Haloperidol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15 to 45 mg)
Study: 29260507
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with bortezomib and dexamethasone (DVd)
Study: 12009297
Drug: Polysaccharide Nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide Nm vaccine
Study: 2287557
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of pentoxifylline and theophylline
Study: 2287557
Drug: Theophylline administration
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline administration alone
Study: 31825075
Drug: High-carbohydrate beverage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate beverage (CHO; 210 kcal; 0 g fat/56 g carbohydrates/0 g protein)
Study: 31229045
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with reduced-concentration tacrolimus and steroids
Study: 31229045
Drug: Mycophenolate, tacrolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate, tacrolimus, and steroids
Study: 23688534
Drug: Luteolin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteolin and quercetin dietary supplement (100 mg luteolin, 70 mg quercetin, 30 mg rutin per capsule, 1 capsule per 10 kg weight per day with food)
Study: 23688534
Drug: Luteolin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteolin and quercetin dietary supplement
Study: 12496059
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (part of nicotine replacement therapy)
Study: 6444379
Drug: 20 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 percent benzoyl peroxide lotion
Study: 28947449
Drug: Lifestyle Matters
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle Matters intervention (4-month occupational therapy intervention)
Study: 25824586
Drug: Valacyclovir (vACV)
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir (vACV) 8 g/day
Study: 25824586
Drug: Valganciclovir (vGCV)
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valganciclovir (vGCV) 900 mg/day
Study: 23429202
Drug: Avatar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatar therapy
Study: 23429202
Drug: Crossover control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover control (TAU vs Avatar therapy)
Study: 17220051
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (rosiglitazone 8 mg)
Study: 17220051
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (rosiglitazone 8 mg)
Study: 12644428
Drug: L-bupivacaine 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-bupivacaine 0.75% and lidocaine 2%
Study: 8529086
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and educational cardiac rehabilitation program, including 6 weekly group sessions and personalized behavior modification program.
Study: 7008293
Drug: Standard antirejection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antirejection treatment (SAT)
Study: 31773201
Drug: ISB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISB with DEX (1 ml DEX + 8 ml 0.75% ropivacaine)
Study: 31773201
Drug: ISB alone
Normalized name: ISB 1342
DrugBank: ISB 1342 (DB17251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISB alone (1 ml normal saline + 8 ml ropivacaine)
Study: 31663769
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (o‐CEE; n = 109)
Study: 31663769
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (t‐E2; n = 107)
Study: 26600287
Drug: Topical overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical overnight application of lidocaine for 10 weeks
Study: 26600287
Drug: Topical overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical overnight application of lidocaine
Study: 11976562
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g young barley leaf extract (BL)
Study: 11976562
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vitamin C and 200 mg vitamin E (CE)
Study: 11276473
Drug: Optimum medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum medical management (risk factor reduction and initiation of antiplatelet therapy)
Study: 29405226
Drug: Solanezumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanezumab (400 mg) every 4 weeks for 80 weeks
Study: 29405226
Drug: Solanezumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanezumab (400 mg)
Study: 28370397
Drug: Comprehensive education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive education about dental implants delivered before the interview
Study: 28370397
Drug: Comprehensive education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive education about dental implants delivered after completing the questionnaire
Study: 28370397
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about implants from relatives or own dentist
Study: 28370397
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about implants from the study dentist
Study: 21250860
Drug: Alcaftadine 0.25%
Normalized name: ALCAFTADINE 0.25% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcaftadine 0.25% ophthalmic solution
Study: 19994698
Drug: Wooden needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wooden needle treatment
Study: 19994698
Drug: Alprazolam (western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (western medicine)
Study: 7487127
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg/day)
Study: 7654434
Drug: Ondansetron (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (24 mg/day)
Study: 7654434
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg/day) in patients receiving cisplatin
Study: 7654434
Drug: Ondansetron (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (24 mg/day) in patients receiving cisplatin
Study: 7654434
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg/day) in patients receiving ifosfamide
Study: 7654434
Drug: Ondansetron (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (24 mg/day) in patients receiving ifosfamide
Study: 31039656
Drug: Metformin sterosomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin sterosomes
Study: 31039656
Drug: Metformin-free solution
Normalized name: metformin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-free solution aerosol
Study: 31039656
Drug: Metformin sterosomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin sterosomes and metformin-free solution aerosol
Study: 27465727
Drug: Enzyme-Treated Asparagus
Normalized name: Asparagus
DrugBank: Asparagus (DB10503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-Treated Asparagus Extract (ETAS) 150 mg/d for 28 days
Study: 22510424
Drug: Lixivaptan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixivaptan 100 mg once daily
Study: 21037433
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (oxaliplatin- or irinotecan-based, at least 3 cycles)
Study: 17960520
Drug: Intrahospital supervised
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrahospital supervised exercise training (3 weekly sessions of resistance and aerobic training for 8 weeks)
Study: 10584996
Drug: Nadroparin administered
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin administered by the venous line
Study: 10584996
Drug: Nadroparin administered
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin administered by the arterial line
Study: 10584996
Drug: Nadroparin with
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin with part of the dose added to the priming solution
Study: 10584996
Drug: Nadroparin administration
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin administration (both routes)
Study: 8712133
Drug: Baseline fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline fibrinogen concentration > or = 300 mg/dl
Study: 6354929
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg t.i.d.
Study: 6354929
Drug: Captopril 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 37.5 mg b.i.d.
Study: 6354929
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 12.5 mg
Study: 6354929
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 25 mg
Study: 6354929
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 37.5 mg
Study: 6354929
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 50 mg
Study: 30683103
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel and oral tablets for HIV prevention
Study: 27734104
Drug: hyperinsulinaemic hypoglycaemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperinsulinaemic hypoglycaemia (HH; i.v. bolus of 0.1 U/kg insulin)
Study: 27734104
Drug: hyperinsulinaemic euglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperinsulinaemic euglycaemia (HE; i.v. bolus of 0.1 U/kg insulin and 20% glucose)
Study: 15227557
Drug: Sequential Multi
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Multi Layered Perceptron (SMLP)
Study: 7949205
Drug: Aminoglutethimide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (500 mg daily)
Study: 7949205
Drug: Aminoglutethimide (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (lower dose without hydrocortisone)
Study: 7949205
Drug: Aminoglutethimide (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (lower dose)
Study: 7949205
Drug: Aminoglutethimide (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (initial high dose)
Study: 17010995
Drug: FEWP monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEWP monotherapy (36 g/day, n=86)
Study: 15095554
Drug: TPA (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA (standard 0.9 mg/kg TPA therapy)
Study: 7640924
Drug: iomeprol 350
Normalized name: Iomeprol 350 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 350 mg I ml‐1
Study: 7640924
Drug: iohexol 350
Normalized name: iohexol 350 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 350 mg I ml‐1
Study: 7640924
Drug: iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol 370 mg I ml‐1
Study: 2520297
Drug: Daily vitamin‐mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin‐mineral supplement containing 2 or 3 mg of vitamin B6 for 9 days before surgery and multivitamin supplement containing 0.4, 0.8 or 2 mg of vitamin B6 for 3 months postoperatively
Study: 2520297
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of supplemental vitamin B6 per day during the fourth month
Study: 31246878
Drug: BWL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BWL therapy (30-minute exposure to waking white light enriched with blue for 4 weeks)
Study: 31246878
Drug: N-BWL (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-BWL (no light therapy)
Study: 23958818
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone
Study: 14699198
Drug: Multiple-family group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-family group treatment
Study: 2173435
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily (4000 anti Xa U)
Study: 2173435
Drug: Unfractionated calcic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated calcic Heparin (5000 U.I. every eight hours)
Study: 73013
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of A.M.L. cells and B.C.G. given on 4 occasions early in remission
Study: 73013
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with killed allogeneic A.M.L. cells and Glaxo B.C.G. (Control group)
Study: 28225297
Drug: Simethicone (co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (co-administered with CIN)
Study: 21723989
Drug: 4-implant bar
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-implant bar attachment
Study: 21723989
Drug: 2-implant bar
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-implant bar attachment
Study: 21723989
Drug: Criterion-based retention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Criterion-based retention scores for all treatments
Study: 21723989
Drug: O-ring treatment
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O-ring treatment
Study: 21723989
Drug: 4-implant bar
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-implant bar treatment
Study: 19403468
Drug: Zolpidem at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day)
Study: 12765594
Drug: Bemiparin (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (heparin of low molecular weight), injected subcutaneously at 3500 IU/day for the first 10 days and 2500 IU/day up to 90 days
Study: 8951932
Drug: Bosentan 250
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 250 mg i.v.
Study: 1955637
Drug: SMX168-poly-L-tyrosine skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMX168-poly-L-tyrosine skin test reagent
Study: 7048919
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent topical acyclovir ointment
Study: 25551475
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) treatment
Study: 23850491
Drug: Sitimagene ceradenovec
Normalized name: Sitimagene ceradenovec
DrugBank: Sitimagene ceradenovec (DB04907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitimagene ceradenovec (1×10^12 viral particles) followed by ganciclovir (5 mg/kg intravenously twice a day) in addition to standard care
Study: 16415304
Drug: CEE/MPA (0.625/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (0.625/2.5 mg daily)
Study: 12571649
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to eat two portions of oily fish each week or take three fish oil capsules daily
Study: 9199864
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) treatment for two weeks
Study: 3978008
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine 6.25 mg h‐1 infusion
Study: 3978008
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 10 ml h‐1 infusion
Study: 3978008
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 12.5 mg h‐1 infusion
Study: 3978008
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 18.75 mg h‐1 infusion
Study: 22388476
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (medication or cognitive-behavioral therapy)
Study: 22388476
Drug: Remission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission of mothers' depression (regardless of treatment assignment)
Study: 18755319
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg calcium carbonate plus 400 IU vitamin D(3) per day
Study: 8743187
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation for 6 months
Study: 6356756
Drug: Diazepam (0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.17 mg/kg)
Study: 29595123
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination formulation (salbutamol 4 mg and ambroxol 15 mg)
Study: 29595123
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of salbutamol 4 mg and ambroxol 15 mg
Study: 29595123
Drug: Ambroxol 15
Normalized name: ambroxol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 15 mg